Evommune, Inc. (EVMN)

Evommune Statistics

Total Valuation

Evommune has a market cap or net worth of $539.69 million. The enterprise value is $464.40 million.

Market Cap	539.69M
Enterprise Value	464.40M

Important Dates

The last earnings date was Thursday, December 11, 2025, after market close.

Earnings Date	Dec 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Evommune has 31.52 million shares outstanding. The number of shares has increased by 22.66% in one year.

Current Share Class	31.52M
Shares Outstanding	31.52M
Shares Change (YoY)	+22.66%
Shares Change (QoQ)	+0.28%
Owned by Insiders (%)	2.76%
Owned by Institutions (%)	6.06%
Float	15.72M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.02
Forward PS	n/a
PB Ratio	7.31
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	35.72
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.87, with a Debt / Equity ratio of 0.01.

Current Ratio	7.87
Quick Ratio	7.30
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-5,600.69

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-98.22%
Revenue Per Employee	$288,889
Profits Per Employee	-$1.40M
Employee Count	45
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	44.90
Average Volume (20 Days)	210,735

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Evommune had revenue of $13.00 million and -$62.82 million in losses. Loss per share was -$40.87.

Revenue	13.00M
Gross Profit	13.00M
Operating Income	-72.81M
Pretax Income	-61.32M
Net Income	-62.82M
EBITDA	-71.39M
EBIT	-72.81M
Loss Per Share	-$40.87

Balance Sheet

The company has $76.06 million in cash and $765,000 in debt, giving a net cash position of $75.30 million or $2.39 per share.

Cash & Cash Equivalents	76.06M
Total Debt	765,000
Net Cash	75.30M
Net Cash Per Share	$2.39
Equity (Book Value)	73.87M
Book Value Per Share	-117.78
Working Capital	71.53M

Cash Flow

In the last 12 months, operating cash flow was -$78.25 million and capital expenditures -$131,000, giving a free cash flow of -$78.39 million.

Operating Cash Flow	-78.25M
Capital Expenditures	-131,000
Free Cash Flow	-78.39M
FCF Per Share	-$2.49

Margins

Gross Margin	100.00%
Operating Margin	-560.07%
Pretax Margin	-471.72%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Evommune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.66%
Shareholder Yield	-22.66%
Earnings Yield	-11.64%
FCF Yield	-14.52%

Analyst Forecast

The average price target for Evommune is $39.33, which is 129.73% higher than the current price. The consensus rating is "Buy".

Price Target	$39.33
Price Target Difference	129.73%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Evommune has an Altman Z-Score of -4.87. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.87
Piotroski F-Score	n/a